New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 13, 2012
07:36 EDTNBYNovaBay provides outlook for FY13
Dr. Ron Najafi, chairman and CEO, said, "2012 was an exciting year for NovaBay. As a result of the hard work from our talented employees and partners, all three of our Aganocide programs, in ophthalmology, dermatology, and urology, are currently in Phase 2 clinical trials. Data is expected from all of these trials in 2013. We plan to use our recent $7M financing to accelerate and expand these clinical trials," Dr. Najafi continued. "For example, we anticipate that these funds will allow us to speed enrollment of patients with additional sites in our global Phase 2b study for adenoviral conjunctivitis. Additionally, we intend to use proceeds from this financing to conduct a Phase 2 study of NVC-422 in bacterial conjunctivitis. We believe that having one product to treat both bacterial and viral conjunctivitis will place NovaBay in a leading position in the market. NVC-422 has the potential to be the conjunctivitis prescription, without need for a test to determine if a patient has the bacterial or the viral form of the disease."
News For NBY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 26, 2015
09:15 EDTNBYNovaBay reports Q4 EPS (9c), one estimate (7c)
Reports Q4 revenue $385,000, one estimate $60,000. "Avenova sales in February were double January sales, and sales in March are well outpacing those in February. We are making progress on the second component of our plan of introducing innovative eye care products to leverage our salesforce. We expect to introduce a cream version of Avenova for overnight use and are developing additional products that we plan to launch in the coming 12 to 18 months.," said the company. Cash, cash equivalents and short-term investments were $5.4M as of December 31.
March 16, 2015
07:07 EDTNBYNovaBay says 3Q14 Avenova sales about $90,000, Q4 sales about $219,000
07:07 EDTNBYNovaBay sees 1Q15 Avenova sales 'well above' level of Q3, Q4 combined
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use